Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the objective response rate (ORR) of SAR240550 administered as a 60min intravenous infusion twice weekly (arm A) or weekly (arm B), in combination with gemcitabine/carboplatin chemotherapy regimen in patients with metastatic Triple Negative Breast Cancer (mTNBC)
Critère d'inclusion
- Metastatic Triple Negative Breast Cancer